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Abstract
The Chinese researchers have made significant progress in studying rare diseases in the recent years. From 2000 to
2014, 269 out of 1892 clinically relevant original research papers published on high impact journals by Chinese
institutions, and 2678 out of 6040 clinical trials conducted by Chinese institutions and registered at ClinicalTrial.gov
are focused on rare diseases. The number of research papers and of clinical trials has shown a steady trend of
increase. Creating public databases for rare disease will escalate progress in rare disease and enable multicenter
studies.
Keywords: Rare disease, China, Research papers, Clinical trials
Introduction
Rare diseases have been receiving increasing public at-
tention in China [1]. Currently, approximately 15.6 mil-
lion people in China are afflicted with rare diseases [2], a
relatively large patient population that can contribute to
and benefit from medical research. The Chinese govern-
ment has taken steps in promoting rare disease aware-
ness, facilitating medical research, and providing patient
resources. Examples are the upcoming establishment of
a Rare Diseases Prevention and Treatment Law and the
foundation of the Chinese Organization for Rare Disor-
ders [3]. In this letter, we would like to highlight the tre-
mendous amount of progress that has been made by
Chinese researchers in the recent years and additional
steps that are currently underway to facilitate future re-
search and collaboration.
Methods and results
First, we searched pubmed.org for original research arti-
cles published by Chinese institutions in high impact
clinical journals from 2000 to 2014. Articles were in-
cluded if they (1) were published in a journal with clin-
ical focus and an impact factor above 10, (2) listed
China as its first affiliation in authors information, (3)
studied human subjects or used human tissues. Per the
European Commission on Public Health, rare diseases
are defined as “life-threatening or chronically debilitating
diseases which are of low prevalence”, or 1 in 2000
people [4]. Overall, 38 journals were included in our
search. There were 1892 clinically relevant papers, 269
(20 %) of which studied rare diseases. There has been a
steady trend of increase in recent years (Fig. 1a). Using
the criteria above, out of the 21 studies published by
Chinese institutions in the Orphanet Journal of Rare
Diseases from 2012 to 2015, 11 studies used human sub-
jects or tissues.
Second, we looked at clinical trials that were con-
ducted by Chinese institutions and registered at Clinical-
Trials.gov from 2000 to 2014. There was a total of 6040
clinical trials, 2678 (44 %) of which studied rare diseases.
There has been an exponential increase of clinical trials
since 2004 (Fig. 1b).
Conclusion
Evidently, multiple centers in China have been studying
rare diseases, resulting in a tremendous increase in the
number of high-quality publications and clinical trials.
However, most of the data are only available to local re-
searchers. There is a need for open data access and a
nationwide data-sharing platform. Examples of public
database include The Cancer Genome Atlas in the
United States and The European Genome-phenome
Archive in Europe [5]. Creating a public database is a
daunting task that requires collaborative efforts by
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researchers in the Chinese medical research commu-
nity. However, its establishment will bring drastic
change to the research environment in China, creating
abundant opportunities for multi-center studies.
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Fig. 1 a The number of original research papers published by Chinese institutions in high impact journals. Letters, comments, and review articles
were excluded. b The number of clinical trials registered by Chinese institutions in a given year at ClinicalTrials.gov. Trials are grouped by the year
of registration
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